AstraZeneca PLC (LON:AZN)
15,110
-108 (-0.71%)
At close: Feb 26, 2026
AstraZeneca Revenue
In the year 2025, AstraZeneca had annual revenue of $58.74B USD with 8.63% growth. AstraZeneca had revenue of $15.50B in the quarter ending December 31, 2025, with 4.11% growth.
Revenue
$58.74B
Revenue Growth
+8.63%
P/S Ratio
5.37
Revenue / Employee
$622.90K
Employees
94,300
Market Cap
234.35B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 58.74B | 4.67B | 8.63% |
| Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | 24.38B | 2.29B | 10.38% |
| Dec 31, 2018 | 22.09B | -375.00M | -1.67% |
| Dec 31, 2017 | 22.47B | -537.00M | -2.33% |
| Dec 31, 2016 | 23.00B | -1.71B | -6.90% |
| Dec 31, 2015 | 24.71B | -1.84B | -6.93% |
| Dec 31, 2014 | 26.55B | 741.00M | 2.87% |
| Dec 31, 2013 | 25.81B | -2.17B | -7.75% |
| Dec 31, 2012 | 27.97B | -5.62B | -16.72% |
| Dec 31, 2011 | 33.59B | 322.00M | 0.97% |
| Dec 31, 2010 | 33.27B | 465.00M | 1.42% |
| Dec 31, 2009 | 32.80B | 1.20B | 3.81% |
| Dec 31, 2008 | 31.60B | 2.04B | 6.91% |
| Dec 31, 2007 | 29.56B | 3.08B | 11.65% |
| Dec 31, 2006 | 26.48B | 2.53B | 10.54% |
| Dec 31, 2005 | 23.95B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| GSK plc | 32.67B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| Convatec Group | 1.81B |
| Spire Healthcare Group | 1.55B |
| CVS Group | 673.20M |
| Genus | 672.80M |
AstraZeneca News
- 12 hours ago - AstraZeneca Prices $2 Bln Three Tranche Bond Offering - Nasdaq
- 19 hours ago - AstraZeneca Launches “A.Catalyst Thailand Hub”: AI-Integrated Health Transformation - Bangkok Post
- 1 day ago - The £168MILLION man: That's how much AstraZeneca boss Pascal Soriot has been paid in 14 years at the top - This is Money
- 2 days ago - AstraZeneca boss Pascal Soriot nets £17.7m in pay and bonuses for 2025 - Evening Standard
- 2 days ago - AstraZeneca boosts CEO Soriot's pay to about $24 million for 2025 - Reuters
- 3 days ago - AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca's Durvalumab in the Treatment of Metastatic Pancreatic Cancer - Benzinga
- 6 days ago - AstraZeneca (AZN) Gains FDA Orphan Designation for Follicular Lymphoma Treatment - GuruFocus
- 6 days ago - FDA Approval For AbbVie/AstraZeneca's Combination Treatment Could Set New Standard For Slow Growing Blood Cancer - Benzinga